Venmax Drugs And Pharmaceuticals Chart
Venmax Drugs And Pharmaceuticals Share Key Metrics
Volume
1837.00
Market Cap
14.03 CR
LTQ@LTP
434@26.55
ATP
26.15
Var Margin
26.04 %
Circuit Range
21.43-32.13
Delivery %
34.89 %
Value
48037.55
ASM/GSM
No
Market Lot
1
Summary
Venmax Drugs And Pharmaceuticals Fundamentals
View MoreP/E Ratio
0
P/B Ratio
0
Div. Yield
0
Sector P/E
63.84
Sector P/B
3.48
Sec. Div. Yield
0.57
Venmax Drugs And Pharmaceuticals Resistance and Support
Pivot 25.86
Resistance
First Resistance
28.67
Second Resistance
30.56
Third Resistance
33.37
Support
First Support
23.97
Second Support
21.16
Third Support
19.27
Venmax Drugs And Pharmaceuticals Corporate Actions
| Date | Agenda |
|---|---|
| 2026-02-07 | Quarterly Results |
Venmax Drugs And Pharmaceuticals News
Venmax Drugs and Pharmaceuticals Ltd - 531015 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Venmax Drugs & Pharmaceuticals confirmed it does not meet the 'Large Corporate' criteria as per SEBI regulations regarding fund raising via debt securities. This clarifies its compliance status as of March 31, 2026, under the August 10, 2021 circular.
Apr 14 2026 16:04:00
Venmax Drugs and Pharmaceuticals Ltd - 531015 - Announcement under Regulation 30 (LODR)-Change in Management
Venmax Drugs board approved the appointment of two Additional Directors: Mrs. Padmaja Kalyani Sadhanala and Mr. Revoor Ramachandra. These appointments are effective March 30, 2026, and are subject to shareholder approval.
Mar 30 2026 17:03:00
About Venmax Drugs And Pharmaceuticals AboutThe
NSE : 0
BSE : 531015
ISIN : INE154G01022
Yenkey Drugs and Pharmaceuticals Ltd. was originallyincorporated on 28th September 1988 in the name of YenkeyMedico Drugs Private Limited. The Company has beenconverted into a public limited company on 3rd Feb''95 interms of a special resolution passed on 23.01.95 underSection 31(1)/44 of the Companies Act 1956. Accordinglythe Company has obtained a fresh Certificate ofIncorporation consequent on the conversion from theRegistrar of Companies Andhra Pradesh vide ref. no.01-09102 dated 3rd February 1995.The Company is producing bulk drug intermediates asdetailed above and marketing in the domestic markets. Thetotal turnover of the Company is Rs. 89.70 lacs for theyear ended March 1994. Now the Company proposes to expandthe existing capacity of dye and drug intermediate viz; ECAand diversifying into manufacturing of high value chemicalsand bulk drugs viz; Sodium Azide and Vitamin B2 Phosphate.The Company is also proposing to set up a R & D Unit formaintaining high quality control standards of foreignbuyers.
Venmax Drugs And Pharmaceuticals Management
| Name | Position |
|---|---|
| Priyanka Agarwal | Company Secretary & Compliance Officer |
| Venkata Rao Sadhanala | Whole Time Director |
Venmax Drugs And Pharmaceuticals Similar Stocks
Venmax Drugs And Pharmaceuticals FAQs
